trending Market Intelligence /marketintelligence/en/news-insights/trending/HBewi0PSRx8qI35lO-ANQg2 content
Log in to other products

Login to Market Intelligence Platform

 /

Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *

  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Generation Bio closes $110M series C round

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Street Talk - Ep. 64: Coronavirus jumpstarts digital adoption

Street Talk Podcast

Street Talk - Ep. 63: Deal talks continue amid bank M&A freeze, setting up for strong Q4

Street Talk Podcast

Street Talk - Ep. 62: 'Brutal' outlook for oil demand offers banks in oil patch no relief


Generation Bio closes $110M series C round

Generation Bio Co. secured $110 million in series C funding led by T. Rowe Price Group Inc. funds and accounts.

Farallon Capital Management LLC and Wellington Management Co. LLP also participated in the round, alongside existing backers Atlas Venture LP, Fidelity Management & Research Co., The Invus Group LLC, Casdin Capital LLC, Deerfield Management Co. LP, Foresite Capital Management LLC and an entity related to SVB Leerink LLC.

The gene therapy-focused biotechnology company will use the new capital to move its two liver-targeted programs for hemophilia A and phenylketonuria into investigational new drug-enabling studies and clinical development.

Cowen was the exclusive placement agent for the funding round.